National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Olaparib (Lynparza®) monotherapy for the maintenance treatment of adult patients with PSR high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

 

NCPE Assessment Process Complete
Rapid review commissioned 19/09/2018
Rapid review completed 01/10/2018
Rapid Review outcome The NCPE recommend  a full HTA to assess the clinical effectiveness and cost effectiveness of olaparib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 16/10/2018
Pre-submission consultation with Applicant 26/11/2018
Submission received from Applicant 28/06/2019
Current Status Submission received from Applicant